Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide

Shi, Ming-Der; Lin, Hui-Hsuan; Lee, Yi‐Che; Chao, Jian-Kang; Lin, Rong-An; Chen, Jing-Hsien

doi:10.1016/j.cbi.2008.06.006

Cited by 105 publications

(77 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This compound reduces the expression of cyclin D1 and CDK4 and hence the formation of active cyclin D1/CDK4 complex in human colorectal carcinoma Lovo cells. 20 AG also induces p27 while decreasing CDK4 expression in rheumatoid arthritis fibroblast-like synoviocytes. 21 Our data show effect of AG on Cyclin E2, a G1 phase cyclin that is expressed in a tissue specific manner and at very low levels in non-neoplastic cells.…”

Section: Discussionmentioning

confidence: 91%

Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors

et al. 2016

View full text Add to dashboard Cite

Despite state of the art cancer diagnostics and therapies offered in clinic, prostate cancer (PCa) remains the second leading cause of cancer-related deaths. Hence, more robust therapeutic/preventive regimes are required to combat this lethal disease. In the current study, we have tested the efficacy of Andrographolide (AG), a bioactive diterpenoid isolated from Andrographis paniculata, against PCa. This natural agent selectively affects PCa cell viability in a dose and time-dependent manner, without affecting primary prostate epithelial cells. Furthermore, AG showed differential effect on cell cycle phases in LNCaP, C4-2b and PC3 cells compared to retinoblastoma protein (RB ¡/¡ ) and CDKN2A lacking DU-145 cells. G2/M transition was blocked in LNCaP, C4-2b and PC3 after AG treatment whereas DU-145 cells failed to transit G1/S phase. This difference was primarily due to differential activation of cell cycle regulators in these cell lines. Levels of cyclin A2 after AG treatment increased in all PCa cells line. Cyclin B1 levels increased in LNCaP and PC3, decreased in C4-2b and showed no difference in DU-145 cells after AG treatment. AG decreased cyclin E2 levels only in PC3 and DU-145 cells. It also altered Rb, H3, Wee1 and CDC2 phosphorylation in PCa cells. Intriguingly, AG reduced cell viability and the ability of PCa cells to migrate via modulating CXCL11 and CXCR3 and CXCR7 expression. The significant impact of AG on cellular and molecular processes involved in PCa progression suggests its potential use as a therapeutic and/or preventive agent for PCa.

show abstract

Section: Discussionmentioning

confidence: 91%

Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors

et al. 2016

View full text Add to dashboard Cite

show abstract

“…doxorubicin through inhibition of STAT3 activity, suggesting a potential therapeutic strategy using andrographolide in combination with conventional chemotherapeutic agents for treatment of cancer. 53 Andrographolide induces cell cycle arrest 21 and triggers apoptosis in human cancer cells. 54 We have previously demonstrated that andrographolide inhibits DU145 cell growth in vitro and in vivo via suppression of the IL-6 signaling pathway.…”

Section: Discussionmentioning

confidence: 99%

“…18,19 Numerous studies demonstrate that andrographolide exhibits anticancer activity by inducing apoptosis and cell cycle arrest. [20][21][22] Andrographolide possesses strong anti-inflammatory activity 23 and triggers apoptosis via the caspase-8-dependent pathway in human cancer cells. 24 Our previous study has demonstrated that andrographolide significantly inhibits DU145 and PC-3 cells in vitro and in vivo by blocking interleukin (IL)-6-stimulated Stat3 activation.…”

Section: Introductionmentioning

confidence: 99%

Andrographolide Targets Androgen Receptor Pathway in Castration-Resistant Prostate Cancer

et al. 2011

View full text Add to dashboard Cite

Androgen receptor (AR) signaling not only plays a pivotal role in the development of androgen-dependent prostate cancer but is also important in the growth and survival of castration-resistant prostate cancer (CRPC). The first line of treatment of androgen-dependent prostate cancer is the use of androgen deprivation therapy. However, most patients will eventually relapse due to development of CRPC. Thus, development of a strategy to target AR for treatment of CRPC is urgently needed. The authors have previously identified andrographolide as an inhibitor of interleukin-6, which can suppress tumor growth of prostate cancer cells by screening compounds from the Prestwick Natural compound library. In this study, they identified that andrographolide can inhibit AR expression and prostate cancer cell growth and induce apoptosis. Andrographolide is able to down-regulate AR expression at both mRNA and protein levels, prevents its nuclear translocation, and inhibits transactivation of its target genes. Andrographolide prevents the binding of Hsp90 to AR, resulting in proteasome-mediated AR degradation. Furthermore, andrographolide inhibits castration-resistant C4-2 cell growth by reducing AR expression and activity. Thus, andrographolide can be developed as a potential therapeutic agent for prostate cancer by inhibition of androgen receptor signaling.

show abstract

“…Finally, TRAIL gene therapy and radiotherapy target different phases of the cell cycle. The G1 or S phases being most responsive to TRAIL (41,42) and the G1 and G2 phases being most radiosensitive (43,44). Our data showed a higher proportion in S phase after irradiation and a higher proportion in G1 phase with transfection of pEgr.1-TRAIL (Fig.…”

Section: Discussionmentioning

confidence: 99%

Enhanced radiosensitivity of SW480 cells via TRAIL up-regulation mediated by Egr-1 promoter

Ouyang²,

Wu³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Radiosensitization of cancer cells to irradiation could improve the efficacy of radiotherapy. The early transcriptional factor (Egr-1) promoter induced expression of downstream genes after irradiation. TNF-related apoptosisinducing ligand (TRAIL) is known to induce apoptosis in malignant cells, but displayed little or no toxicity on normal cells. In this study, we constructed pcDNA3.1-Egr-1-TRAIL (pEgr.1-TRAIL) recombinant plasmid and evaluated its effect on human colon cancer cell line SW480. pEgr.1-TRAIL transfection combined with radiotherapy caused dramatically elevation of TRAIL expression both in mRNA and protein levels, much lower radiobiological parameters in clonogenic assays, accompanied by remarkably increase in apoptosis ratio. Furthermore, pEgr.1-TRAIL transfected cells displayed higher proportion in G0/G1 phase. Our results suggested that pEgr.1-TRAIL can sensitize SW480 cells to radiation, and the radiosensitization is related to cell cycle changes and apoptosis mediated by up-regulation of TRAIL expression. These findings support the potential future application of genetic radiotherapy against carcinoma.

show abstract

Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide

Cited by 105 publications

References 41 publications

Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors

Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors

Andrographolide Targets Androgen Receptor Pathway in Castration-Resistant Prostate Cancer

Enhanced radiosensitivity of SW480 cells via TRAIL up-regulation mediated by Egr-1 promoter

Contact Info

Product

Resources

About